Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

AI Stock Picker
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Resources

Blog
Earnings
Partner Program

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RXRX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
RXRX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

RXRX Revenue Forecast

RXRX EPS Forecast

RXRX FAQs

What is bull’s view on RXRX?

RXRX stock is currently trading at $7.43, with a bullish outlook supported by its recent cross above the 200-day moving average, indicating potential upward momentum. Analysts maintain a positive stance, with a price target of $10–$11, reflecting a 35%-45% upside driven by its AI-driven drug discovery platform and collaborations with major pharmaceutical companies. However, near-term catalysts are limited, suggesting a longer-term investment horizon.

What is bear's view on RXRX?

RXRX stock closed at $7.24 on January 31, down 5.85% during regular trading. Bears may argue that its high short interest (18.6%) and lack of near-term catalysts, such as late-stage clinical trial data in 2025, limit upside potential. Additionally, its unprofitability and reliance on collaborations for revenue make it vulnerable to market volatility.

What is RXRX revenue forecast for next quarter？

The market consensus for RXRX's revenue in the upcoming quarter is projected to be approximately $12M USD.

What is RXRX eps forecast for next quarter？

The market consensus for RXRX's eps in the upcoming quarter is projected to be approximately $0.48 USD.

RXRX VS S&P500

Ask Intellectia about RXRX

RXRX Analyst's Forecast

Scott Schoenhaus

Keybanc

Buy

2025-01-08

Price Target

$12 → $10

Upside

+37.74%

KeyBanc lowered the firm's price target on Recursion Pharmaceuticals to $10 from $12 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of last year but saw a rebound in the last two months following the Trump election. In combination with consensus estimate cuts since the middle of last year, KeyBanc sees attractive buying opportunities in the space in 2025. From a valuation multiple perspective, the firm believes companies with healthy balance sheets and steady free cash flow profiles will see less risk to multiple contraction, even with more modest growth trends. Conversely, it sees the most risk for companies that have challenged balance sheets and limited profitability in the near and longer term.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
AI Stock PickerFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisStock Chart PatternsEarnings TradingAI Screener
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free

Hot Stocks

stocks logo

SUM

Summit Materials Inc

$52.49
0.00%
stocks logo

BSAC

Banco Santander-Chile

$22.4585
1.08%
stocks logo

HESM

Hess Midstream LP

$39.05
0.39%
stocks logo

APPF

Appfolio Inc

$214.05
0.19%
stocks logo

GTLS

Chart Industries Inc

$191.28
-0.65%
stocks logo

WTFC

Wintrust Financial Corp

$129.645
-0.27%
stocks logo

KNX

Knight-Swift Transportation Holdings Inc

$54.26
0.72%
stocks logo

PEGA

Pegasystems Inc

$88.45
-16.63%
stocks logo

RGEN

Repligen Corp

$146.005
0.20%
stocks logo

GAP

Gap Inc

$22.95
2.05%